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The translation of personal genomics to precision medicine depends on the accurate interpretation of the multitude of
genetic variants observed for each individual. However, even when genetic variants are predicted to modify a protein,
their functional implications may be unclear. Many diseases are caused by genetic variants affecting important protein
features, such as enzyme active sites or interaction interfaces. The scientific community has catalogued millions of
genetic variants in genomic databases and thousands of protein structures in the Protein Data Bank. Mapping
mutations onto three-dimensional (3D) structures enables atomic-level analyses of protein positions that may be
important for the stability or formation of interactions; these may explain the effect of mutations and in some
cases even open a path for targeted drug development. To accelerate progress in the integration of these data
types, we held a two-day Gene Variation to 3D (GVto3D) workshop to report on the latest advances and to
discuss unmet needs. The overarching goal of the workshop was to address the question: what can be done
together as a community to advance the integration of genetic variants and 3D protein structures that could not
be done by a single investigator or laboratory? Here we describe the workshop outcomes, review the state of the
field, and propose the development of a framework with which to promote progress in this arena. The framework will
include a set of standard formats, common ontologies, a common application programming interface to enable
interoperation of the resources, and a Tool Registry to make it easy to find and apply the tools to specific analysis
problems. Interoperability will enable integration of diverse data sources and tools and collaborative development of
variant effect prediction methods.Background
Recent progress in DNA-sequencing technologies has
ushered in an era of rapid and cost-effective genome se-
quencing, enabling clinical applications [1] and the po-
tential for personalized systems medicine [2] through
the understanding of an individual’s genetic risks and by
integration with longitudinal phenotype measurements* Correspondence: Gustavo@SystemsBiology.org
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poses a significant interpretation challenge: while genetic
variants disrupting transcript structure and protein-
coding sequences (for example, nonsense mutations)
have long been considered “low hanging fruit” relative to
variants in non-coding sequences, the field still struggles
with interpreting missense mutations, which are more
common, and more frequently associated with disease
[4]. This has led to an increasing number of variants of
uncertain significance (VUS). To address the resultingle is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
Glusman et al. Genome Medicine  (2017) 9:113 Page 2 of 10annotation and reporting challenges [5, 6], the American
College for Genetics and Genomics (ACMG) and the
Association for Molecular Pathology (AMP) have re-
leased variant interpretation guidelines based on patho-
genicity [7]. The interpretation of variants relies on a
combination of multiple lines of evidence, including the
frequency of the variant in the population (common var-
iants are less likely to be pathogenic), the mode of segre-
gation in pedigrees (for example, de novo mutations not
observed in parents are more likely to be pathogenic
than those that are inherited), the mode of presentation
in affected individuals (for example, single dominant
variant, single variant in homozygous state, two variants
in compound heterozygous state), the predicted effect
on RNA and protein sequence and structure, and prior
knowledge accumulated in curated databases. Many
computational tools have been developed to support
these assessments (Additional file 1: Table S1). However,
multiple challenges remain in the rapidly evolving field
of clinical variant interpretation, including differences in
allele frequency among different populations, a growing
but still incomplete understanding of how variants affect
gene regulation, the sequence and structure of RNA and
protein products, and the partial, inconsistently presented
and sometimes conflicting knowledge in databases.
To assess the potential pathogenicity of genetic vari-
ants, singly or in combinations, it is useful to assess their
frequency in control or general populations, as already
mentioned. Public databases are burgeoning with infor-
mation about genetic variants in humans and in many
model organisms. Resources such as dbSNP [8], dbVar
[9], COSMIC [10], cBioPortal [11], UniProt [12], Kaviar
[13], Clinvar [14], HGMD [15], ExAC, and gnomAD
[16] provide data on hundreds of millions of single-
nucleotide variants (SNVs) and other types of genetic
variations. Each database has a different focus, different
sources of data, processing methods, level of coverage,
and degree of metadata associated with each variation;
some focus only on human variation, while others cover
many species. Similarly, each database has differing
mechanisms for data access and differing levels of cross-
referencing.
The biomedical research community is fortunate to
have access to such a wealth of information, but its sheer
size and disparate nature are also daunting. In addition
to public databases, hundreds of DNA- and RNA-
sequencing experiments are revealing manifold genetic
variants and mutations each year, and an increasing
number of these can be linked to protein structure. For
example, protein structure analysis of a novel variant in
the ubiquitin-protein ligase TRIM11, observed in indi-
viduals affected with inflammatory bowel disease, helped
determine that the variant is more likely to affect pro-
tein–protein interactions rather than protein folding andstability [17]. Functionally important somatic variants in
cancer may form statistically significant spatial clusters
in three-dimensional protein structure, which are not
detectable in one-dimensional sequence, such as kidney-
cancer-specific variants in the tumor suppressor gene
VHL, which are proximal to the binding site of VHL for
its ubiquitination target HIF1A [18].
Simultaneously, there has been great progress in char-
acterizing the 3D structures of proteins [19, 20], both
experimentally and computationally. Essentially, all pub-
licly available experimentally derived structures are
deposited in the Protein Data Bank (PDB) [21]. When
experimentally determined structures are not available
for proteins, structural models may be used instead. Pro-
tein Model Portal [22] aggregates precomputed models
from multiple resources, whereas most methods generate
models interactively on request, for example, I-TASSER
[23], ModWeb [24], Phyre2 [25], HHpred [26], or SWISS-
MODEL [27]. Currently available homology models with
40–50% sequence identity to experimental structures
already cover approximately 40% of the residues in the hu-
man proteome [28], although this does not always include
the full-length protein in the correct quaternary structure,
but often only specific domains. Beyond simply having 3D
models of proteins, it is crucial to annotate the functional
substructures in these models with such information as
the locations of ligand-binding and active sites, functional
domains, regions that are externally accessible versus in
the protected interior, protein–protein interaction inter-
faces, and other structural features that might be related
to function [29].
However, the connections between genetic variations
and protein structure are not always easy to find. A few
computational tools have begun to emerge (cBioPortal
[11], COSMIC-3D [30], CRAVAT [31], Jalview [32],
MuPIT [33], MutDB [34], STRUM [35], Cancer3D [36])
that enable users to take individual genetic variations, or
a list of them, and visualize these in the context of pro-
tein structures. For example, CRAVAT [31] allows a user
to upload a variant call format (VCF) file [37] (a file for-
mat used for representing DNA sequence variations)
containing many genetic variants and assess which of
those variants map to proteins, and then to explore indi-
vidual variants in a 3D visualization of each protein
when available. STRUM [35] allows users to visualize
the structural model of a protein while, in addition, pro-
viding the profiles of the folding free-energy changes in-
duced by the single-nucleotide polymorphisms (SNPs)
or mutations. The starting point of STRUM is the wild-
type sequence with SNPs or mutations, whereas I-
TASSER is used to generate 3D protein models from
which the impact of genetic mutations on protein stabil-
ity can be more accurately calculated compared with the
sequence-based approaches. Other tools, such as Jalview
Glusman et al. Genome Medicine  (2017) 9:113 Page 3 of 10[32], provide a workbench for exploring variants in con-
text with multiple sequence alignments, molecular struc-
tures, and annotations. COSMIC-3D and cBioPortal [11]
map and visualize variants in their databases on 3D pro-
tein structures. The VIPUR pipeline [38] goes one step
further and allows automatic interpretation of the effect
of the mutation on the protein structure. The input to
VIPUR is the wild-type sequence and the mutation of
interest, and, based on the availability of a known struc-
ture or homology model, the tool maps the mutation
onto the structure, and uses Rosetta [39] energy terms
(Box 1) as indicators to report which features are most
strongly affected by the mutation. Broad mining of data
across thousands of proteins and millions of variants re-
mains challenging due to the computational cost of
structure modeling and the limited availability of experi-
mental structures and high-fidelity models.
The confluence of genetic variation information and
protein structure knowledge has broad applications
across multiple fields of study, including precision medi-
cine [40]. A future is conceivable in which an individual’s
genetic variants are uploaded to an intelligent system
that can flag variants for previously documented func-
tional alterations, and then enable a clinician or genetic
counselor to explore the potential implications for health
and disease, based on the predicted effects of these vari-
ants on the functions of individual proteins. Similarly,
decisions about which therapies are indicated may be in-
fluenced or directly based on the known function of a
drug as it relates to potential variants on the drug’s tar-
get protein. Such a system remains distant, but the time
is right for developing an infrastructure that wouldBox 1. Glossary
Benchmark dataset: A curated and well-studied dataset that can
be used to evaluate the relative performance of analysis
methods and algorithms.
File parser: A computer program module that interprets the
structure of input data and breaks the input into well-defined
parts that can then be used by other parts of the computer
program.
Rosetta energy terms: Rosetta [39] estimates the energetic
stability of protein structures as a sum of energy terms,
including hydrogen bonding, electrostatic interaction, attractive
and repulsive interaction, and solvation terms.
Software stack: A set of software subsystems or components
designed to work together as a platform.
Variant Call Format: A standard format of a text file used for
storing genome sequence variations relative to a reference
genome.enable its development. There are a few ongoing efforts
to curate functional data and disease associations for
cancer variants [41–44]. Efforts to computationally
model the association of various genomic mutations and
human diseases are also underway [45–47].
Although the handful of tools listed above already per-
form an integration of genetic variation and protein
structure data at some level, building infrastructure for
both large-scale integration as well as broader usage of
tools in the laboratory and in the clinic has yet to be
achieved. Large-scale data integration for millions of
variants, thousands of genomes, and tens of thousands
of structures on platforms such as Apache Spark [48]
and Google BigQuery [49, 50] will enable complex
queries and machine-learning approaches to further
learn how to predict functional implications of de-
tected variants.
In order to accelerate progress in this field, we held a
workshop on this topic at the Institute for Systems Biology
in Seattle in February 2017. Here, we summarize the dis-
cussions and conclusions of this workshop, and present a
comprehensive overview of the field. Finally, we conclude
with a proposed architecture for a framework that could
allow improved interoperability between the tools in this
domain, making it easier for everyone to build on the
accomplishments achieved so far.
The gene variation to 3D workshop
On 9 and 10 February 2017, the Gene Variation to 3D
(GVto3D) workshop was hosted at the Institute for
Systems Biology in Seattle, Washington. The goal of the
workshop was to explore the state of the field connecting
genetic variation and 3D protein structure, and to bring
together some of the key researchers working on inter-
preting genetic variation data. The workshop consisted of
a mixture of talks, discussion sessions, and breakout
groups. The program is available at the workshop website
[51]. Twenty-five speakers provided short (15 minute)
summaries of their research; highlights from the talks are
available from the meeting website [51]. The oral presen-
tations connected the workshop theme to diverse topics
such as RNA sequencing (RNA-seq), big data technolo-
gies, how precision medicine can help with specific
diseases, and cancer research.
After all the presentations and discussion sessions
concluded, workshop participants separated into two
breakout groups to brainstorm about how the research
community as a whole could accelerate progress in the
field in ways that individual laboratories could not.
Breakout group 1 discussed existing ontologies, tools,
and datasets in the field and considered potential archi-
tectures for an integrative framework, focusing on how
tools and resources could be made more interoperable
to enable more widespread use of the tools and
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portant aspects that emerged in the discussion include:
1. Adoption or development of standardized formats
for the various major data types (such as variants,
splice isoforms, post-translational modifications,
structures, sequence annotations, and phenotypes).
2. Mechanisms to scale up the information exchange
to large-scale queries using big data technologies
such as DataFrames [52] and BigQuery [49].
3. Use of ontologies to standardize the terminology
for the exchange of data and knowledge. These
ontologies already mostly exist, and need only be
specified as the standard, although some extension
may be required.
4. Selection of initial tools that should be part of a pilot
phase of the development and initial deployment of
the interoperability framework.
5. Development of a tool registry and portal that
would serve as a web-accessible resource for finding
relevant tools, their inputs and outputs, and also
reference data files that can be used to demonstrate
and validate the tools and their interoperation.
Breakout group 2 discussed unmet needs, ranging
from improvements in structural interpretation of spli-
cing variants to more effective dissemination of know-
ledge to clinical geneticists, tumor panels, and the
general public. Salient questions and points that were
discussed include:
1. How to increase the actionability of variants
observed in patients. Beyond facilitating access to
knowledge on the structural impacts of variants,
there is a need for a metric of confidence in the
predicted impact. Gene-editing technologies are
likely to enhance experimental studies of salient
variants.
2. The need to recognize multi-variant interactions
within single genes and proteins and mutation
effects on protein–protein, protein–nucleic acid,
or protein–ligand and drug interactions. Also,
annotation of the context in which each variant
could have an effect is important. For instance,
information on cell types or cellular conditions in
which specific interactions or protein complexes
are formed, as well as annotation of epistatic
relationships with mutations elsewhere in the
genome, can help in interpreting a mutation’s
influence on the cell.
3. How to improve the interpretation of variants
affecting splicing. A proposal was made to create a
mechanism for collecting donated RNA-seq data to
derive a comprehensive set of splice variants andinterpret them in the context of protein structure.
It may also be useful to organize data on splice
variants by type of alternative splicing
(for example, exon swaps, intron retention, and
coordinated inclusion of distant alternative exons
[53], which are widespread in the human
transcriptome and primarily affect protein
coding exons [54]).
4. How to standardize annotation pipelines and data
integration methods. It was recognized that this has
already been partially solved independently by
various teams, such as mapping genomic positions
onto 3D structures (see “Current State of the Field”),
so there would be a benefit from implementing an
interoperation framework.
5. How to identify the target audiences. Scientists,
tumor boards, clinical geneticists, developers of
targeted drugs, patients, and lay people with an
interest in genetic testing were all identified as
possible audiences.
6. How to improve documentation and outreach.
Suggestions included the development of
documentation videos and tutorials, and
contributing to Wikipedia sections describing
the impact of variants on protein structure,
building on current experience such as the
Protein Standards Initiative [55] of the Human
Proteome Organization.
The workshop has already begun to positively impact
collaboration and interoperability in the wider research
community. For example, an immediate outcome from
discussions that occurred during the workshop was that
links pointing researchers to the MuPIT resource [33]
were added to the Kaviar database of human SNPs [13]
and the PeptideAtlas database of proteins detected via
mass spectrometry [56, 57], so that the variations in the
latter resources can be depicted using the tools in
MuPIT. Engaging members of the research community,
as we have, will enable promising avenues for further
work in this direction, including the design of a frame-
work according to principles of user-centered design.
Before laying out our vision for the framework, however,
we first provide an overview of the field as it stands.
The current state of the field
Here we review methods that use 3D structural informa-
tion from the PDB to predict the effect of missense mu-
tations; mapping other types of mutations (for example,
insertions, deletions, splicing effects) remains an open
challenge. In Table 1, we present an overview of six clas-
ses of prediction methods, summarizing the type of pre-
diction and listing some of their limitations. We have
then reviewed the literature and assigned methods to
Table 1 Classification of methods to predict the effect of missense mutations
Method type Prediction Limitations
Protein stability Predicts the difference in unfolding free energy
between wild-type and mutant protein
Considers only one possible mechanism that
may affect the phenotype
Protein–protein/protein–nucleic
acid affinity
Predicts the difference in the binding affinity
between binding partners upon mutation
Small training datasets limit the scope of these
methods
Protein–ligand affinity Predicts the difference in ligand-binding affinity
upon mutation
Small training datasets limit the scope of these
methods
Phenotypic effect Predicts the likelihood that a mutation is
deleterious without considering a specific
molecular mechanism
Except for Mendelian disease phenotypes, the
phenotype may only be observed in a subset
of the population (partial penetrance).
Databases use different annotation practices
and contain contradictory information for some
mutations
Mapping and 3D visualization Provides a 3D context of the site of mutation
and may give atomic-level insight into
mechanism of action
Visual approach is not suitable for automated
whole-exome predictions
3D mutation hotspots Clusters mutations by spatial proximity that are
not necessarily close in protein sequence
Clustering may not explain the effect of specific
mutations in a hotspot
3D three-dimensional
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tensive summary of over 30 such methods that have
been published in the past decade, and have a current
web presence as a web-based user interface, a web ser-
vice, or a downloadable stand-alone application. In
addition, we have captured tools that rely on sequence
information only. Prediction tools are trained, tested,
and validated on sets of reference proteins and their mu-
tated forms (benchmark datasets). In Additional file 1:
Table S1 we have included a list of benchmark datasets
commonly used to train prediction tools.
A first set of methods predicts thermodynamic
properties related to mutations: (1) change in protein
stability [35, 58–72]; and (2) change in binding affin-
ity for protein–protein [66, 73–78], protein–nucleic
acid [66], and protein–ligand complexes [79]. These
methods have been trained on data from wild-type
and mutant protein pairs, often using protein stability
data from the ProTherm database [80], protein–protein
binding affinities from SKEMPI [81], protein–nucleic acid
binding affinities from ProNIT [80], and protein–ligand
binding affinities from Platinum [82].
A second set of methods [38, 58, 76, 83–88] predicts
the phenotypic effect (pathogenicity) of mutations, most
often as a binary classification: deleterious or neutral ef-
fect. These methods have been trained on data resources
that either contain mostly germline mutations, such as
ClinVar [14], HGMD [15], and OMIM [89], or somatic
mutations, such as the Cancer Genome Atlas (TCGA)
[90] and COSMIC [10]. Carefully selected benchmark
datasets to develop and test prediction methods have
been collected: VariBench [91] and VariSNP [92].
Few prediction methods are purely based on 3D struc-
tural information, with the exception of FoldX [63],
which uses an empirical scoring function to predict thechange in protein stability or protein–protein binding.
Most methods (Additional file 1: Table S1) use a com-
bination of structural and sequence features and then
formulate a regression problem to predict scalar values
(for example, affinity changes), or a classification prob-
lem to predict a mutation as probably deleterious or
neutral. Some methods use homology models to increase
structural coverage, when experimentally determined
structures are not available. The use of structural infor-
mation varies from method to method. FoldX uses the
3D atomic coordinates of the protein, whereas most
methods extract structural features that characterize
changes in the local environment around a mutated
residue [38].
Most tools to predict the effect of mutations are avail-
able online. However, there is a wide variety of input for-
mats and scope of prediction (that is, predicting the
effect of a single or multiple amino acid mutations). The
majority of the 3D protein structure-based tools take
PDB residue numbers of the mutated sites as input
(Additional file 1: Table S1). There are also tools that ex-
ploit structural models predicted by advanced structure
modeling algorithms and demonstrate the usefulness of
structure predictions compared to those using only se-
quences, such as FoldX [63] or BindProfX [78]. A
smaller number of tools use UniProt/Swiss-Prot residue
positions. A minority of tools use chromosome posi-
tion, dbSNP ID [8], or VCF files as input. A few tools
need explicit PDB structures in the wild-type and mu-
tated forms. User interfaces and presentation of results
with the available web resources vary significantly;
some resources require a user registration, and in some
instances results are returned by email.
Several integrated tools have been developed that
combine the prediction of the effects of mutations,
GVto3D portal
GVto3D
mapping
Beacon
PDB
UniProt
Tools registry
3rd 3rd
Standard APIs
Adapters
Tools using APIs
3rd 3rd
Fig. 1 Components of the GVto3D portal. The Tools Registry contains a
searchable description and metadata for tools, resources, and reference
data sets for third-party variant effect prediction and annotation services.
Standardized application programming interfaces (APIs) provide
interoperability for data input and output of these third-party tools.
Custom adapters can provide limited interoperability for tools that
cannot adopt the API. A mapping service provides bidirectional
mappings from reference genome coordinates to UniProt protein
positions and to Protein Data Bank (PDB) residue positions. The tools
can use the mapping service to accept variant positions in any of the
three coordinate systems. A beacon system enables queries about
variant positions where three-dimensional (3D) structural information
and annotation are available
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mapping of mutation sites onto 3D protein structures
and multiple sequence alignments. Examples include
3DHotspots.org [93], cBioPortal [11], COSMIC-3D [10],
CRAVAT [31], Jalview [32], LS-SNP/PDB [94], MOKCA
[95], MuPIT [33], RCSB PDB [21], SNP2Structure [96],
and Cancer3D [36]. These tools might help elucidate the
effect of mutations in the context of both 3D structure
and other available annotations. Ensembl’s Variant Effect
Predictor (VEP) [97] combines several annotation and
prediction services, including various considerations of
effects on protein products.
A biologist who wants to assess the effect of mutations
is confronted with a bewildering set of tools and options.
The high variability in the user interfaces and in the rep-
resentation and retrieval of results makes a systematic
comparison of predictions by multiple tools cumber-
some and requires manual input; hence, most tools are
not applicable to anything but a small set of selected
mutations. A systematic or automated comparison of a
list of mutations (for example, at exome scale) using
multiple tools is generally not possible. For instance, it
would be useful to run tools that predict multiple effects
of mutations simultaneously, such as protein stability
and interruption of protein–protein and protein–nu-
cleic acid binding. A further limitation is the input by
PDB or UniProt residue position, since SNVs are anno-
tated using genomic coordinates. Mapping between
genomic and protein coordinate systems is error prone
due to, for example, different genome assembly ver-
sions and alternative splicing. Where a mapping from
genome to UniProt is possible, SIFTS [98] and CRAVAT
[31] provide consistent residue-level mapping to and from
PDB structures and other resources.
Current tools that predict the effect of missense muta-
tions are based on either protein sequence information,
3D structural information, or both. Tools predict either
biophysical changes or effect on phenotype. Those that
use 3D structural information and visualization offer
additional insights by providing locations of mutations
in a 3D context, which is not possible using sequence-
based prediction. For example, multiple mutations on a
protein can be visualized and potential 3D hotspots can
be identified. In the next section, we describe a frame-
work to overcome the large heterogeneity of tools, which
limits their usefulness, ease of use, and hinders compara-
tive performance assessments.
Proposed framework for making progress as a
community
To facilitate innovation in this field, we recommend the
development of a framework of common formats and
application programming interfaces (APIs) that enable
the many resources available to interoperate moreeffectively both at the individual variant level and at
large scales. We further recommend the development
of a portal that can be used to annotate the current
state of tools in the field and guide users on how these
tools can interoperate and be used to address different
research questions. The outline of the recommended
GVto3D framework takes its lead both from our wider
review of the field as well as from the presentations and
discussions that occurred among those members of the
research community who attended the workshop; its
design incorporates the needs and existing efforts of
these researchers.
Figure 1 depicts the recommended components and
design of the GVto3D framework. The Tools Registry
will act as a central repository of data resources and soft-
ware tools related to genetic variants, protein sequences,
protein structures, variant effect prediction, and variant
annotation. Metadata about each resource to enable
findability of the different software tools will be stored
and offered through an interactive web interface and
also an API, which in turn enables the development of
intelligent software that can automatically discover ap-
plicable resources and gather information about how to
communicate with them to obtain the desired results. In
addition to name, description, citations, contact infor-
mation, and uniform resource locators (URLs), each
entry will contain information important to the tool’s
interoperation, such as the inputs and outputs, API sup-
port, and reference genome information.
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ition of standard APIs so that information can be sent
to and requested from different tools in the same way,
thereby reducing software development overheads,
which are typically encumbered with different tools
using different APIs. It is envisaged that new third-
party tools will use the API natively while API
adapters will be developed in order to bridge with pre-
existing third-party tools. The API enables seamless
interoperability between different variant-related tools
and also a standard access to multidirectional map-
ping among genomic, protein sequence, and protein
structure coordinates. These mappings will be made
available through APIs and as downloadable data files.
Mappings will be kept up to date based on the update
schedules of the underlying data sources (PDB, weekly;
UniProt, monthly), freeing developers from maintain-
ing and updating copies of these data. Once several
similar resources support the standard APIs, the site
can be further developed into an aggregation portal,
where a query at the portal can be automatically
farmed out to multiple resources, and the results col-
lated and returned to the user in a single batch. This
framework advances the FAIR principles of findability,
accessibility, interoperability, and reusability [99] for
all tools and resources that participate.
The use of standard file formats and standardized rep-
resentations of data enable interoperability of prediction
tools, for example, the output from one tool can be passed
as input into a second tool, and can thereby simplify the
comparison of different methods. The standardized for-
mats are also essential components of a reusable set of
integrated tools (software stack), including tools for
reading and interpreting data files (file parsers), APIs, and
visualization tools. Most of the current tools use a variety
of inputs and outputs, placing a large burden on the
user to transform data. Standard file formats and uni-
form APIs will be at the core of future services that
will combine and compare different approaches. Vari-
ous platforms and tools have different schedules and
reliability of upgrades; keeping track of versions is
important as changes to software may have large ef-
fects on the results.
The VCF file format [37], despite its complexity, is
the de facto standard format for storing variant calls for
a wide range of variants, from SNVs to long insertions
and deletions. The Global Alliance for Genomics and
Health’s Data Working Group File Formats Team de-
fines the VCF specification and its evolution [100].
Variant annotations—for example, the results of predic-
tion tools—can be captured in the INFO records, which
are a set of structured records used to add annotation to
VCF files. VCF versions 4.x, including the current version
4.3 [101], define meta-information lines that describe theINFO record data types and enforce standardization [102].
In addition to VCF, a few other formats have been de-
scribed, such as ANN, which defines a different standard
for representing variant information in INFO fields; VEP
[97] supports a simple tab-delimited, as well as JavaScript
Object Notation (JSON) output format.
Regarding genome nomeclature, the Human Genome
Variation Society, which aims to foster the discovery and
characterization of genomic variations, including popu-
lation distribution and phenotypic associations, has
established guidelines and recommendations for the no-
menclature of gene variations, and serves as an inter-
national standard [103].
Progress in this field depends on global collaboration
and the sharing and reuse of tools. APIs provide proto-
cols to enable this collaboration. Tools wrapped in
standard APIs present a consistent interface to heteroge-
neous tools, enhancing interoperability, and shielding
the user from changes to the underlying software. As an
example, many prediction tools that use 3D protein
structural information define the location of mutations
at the protein level using either UniProt or PDB coordi-
nates. Mapping genomic coordinates to 3D protein
structure is non-trivial and error prone. Robust APIs
that can perform this mapping with up-to-date 3D infor-
mation using both types of protein coordinates can aug-
ment existing tools that are based on just linear protein
sequence coordinates.
Moreover, progress in the prediction of the effect of
mutations and use of 3D structural information de-
pend on the availability of well-designed training, test,
and validation sets. The tool repository will be a place
to share datasets, as well as protocols and references
(metadata) for how these datasets were generated. Vali-
dation sets, accompanied by well-documented tutorials
or vignettes, will include a subset of variants with
clearly understood effects that can be used to test the
output of available resources. Eventually these can
serve as a set of unit tests for the framework itself.
Conclusions and future perspectives
The GVto3D workshop held in Seattle in February 2017
represents an important step towards spurring collabor-
ation and advancing progress in proteogenomics research.
The disparate nature of current tools and resources and
lack of interoperability contribute to slower progress in
the field than might otherwise be possible. Development
of a community-driven interoperability framework for in-
tegrating genetic variation resources and protein structure
resources promises further expansion of our understand-
ing of the functional implications of genetic variation.
While the use of 3D structural features has enabled the
atomic-level exploration of the effects of mutations (for
example, the identification of 3D mutation hotspots), the
Glusman et al. Genome Medicine  (2017) 9:113 Page 8 of 10accuracy, scope, and scale of predictions are still limited.
The proposed framework will enable pooling of data
sources and tools, and collaborative development.
However, there will be substantial challenges as we move
forward with design of the framework. The first challenge
is establishing a durable user base for the framework. One
possible approach is to engage a few key laboratories to
take the lead as early adopters, and assume that the frame-
work will gain wider community acceptance through their
example. We propose a more user-centered design ap-
proach, however, which emphasizes an iterative process of
engaging multiple communities of practice in conceptual-
izing, developing, and rolling out the framework; the
GVto3D workshop was a first step in this direction.
Second, questions of sustainability are also pertinent here,
insofar as how such a system will be maintained, and who
will be responsible for its ongoing maintenance. Here, we
propose an approach that we envision will become self-
sustaining through the deployment of open-source tech-
nologies in an engaged community. Third, standardization
is a key component of any interoperability project, which
in this case depends upon work to enhance usage of cer-
tain de facto standards, and to establish other standards,
including the creation of standard APIs. Working closely
with the community of potential framework users, as well
as with standard-setting bodies, such as the Global Alliance
for Genetics and Health and the Proteomics Standards
Initiative of the Human Proteome Organization, will be
important for helping these standards gain further traction.
Taken together, the user-centered framework we have
outlined above—a Tool Registry and a set of standardized
formats and common APIs based on deployment of open-
source materials—aims to bring the FAIR principles to
bear on current and emerging tools while enabling their
broader usage across multiple communities of practice.
The result promises to be more rapid progress in research
that can make use of GVto3D resources and eventual ap-
plications to precision medicine, while ensuring that
methods and outcomes are findable, accessible, interoper-
able, and reusable.Additional files
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structural information from the Protein Data Bank to predict the effect of
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